Related Experiment Video
Updated: Jun 15, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Assessing treatment effects with adjusted restricted mean time lost in observational competing risks data.
Haoning Shen1, Chengfeng Zhang1, Yu Song1
1Department of Biostatistics, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, No. 1023, South Shatai Road, Guangzhou, China.
This study introduces a new method for analyzing treatment effects in cancer patients, considering competing risks. The adjusted restricted mean time lost (RMTL) method provides more accurate and interpretable results for observational data.
Area of Science:
- Biostatistics
- Epidemiology
- Oncology
Background:
- Assessing treatment effects in cancer patients requires accounting for competing risks.
- Traditional metrics like cause-specific hazard ratio (CHR) and sub-distribution hazard ratio (SHR) have limitations in interpretation and assumptions.
- Restricted mean time lost (RMTL) offers a more clinically interpretable measure, especially when adjusted for confounding factors in observational studies.
Purpose of the Study:
- To develop and validate a covariate-adjusted restricted mean time lost (RMTL) estimator for analyzing treatment effects in observational studies with competing risks.
- To evaluate the performance of the proposed estimator through simulation studies.
- To assess treatment effects over time using dynamic RMTL difference curves.
Main Methods:
- Developed an RMTL estimator using inverse probability weighting for covariate adjustment.
- Derived variance for interval estimation based on large sample properties.
- Conducted simulation studies to assess estimator performance across various scenarios.
- Constructed dynamic RMTL difference curves and confidence bands to analyze time-varying treatment effects.
Main Results:
- The adjusted RMTL estimator demonstrated reduced bias and provided robust interval estimates compared to unadjusted RMTL.
- Application to cervical cancer data showed improved prognosis for small cell carcinoma patients.
- Surgery showed a significant protective effect within the first 20 months.
- Radiotherapy improved outcomes between 17-57 months; combined radiotherapy and chemotherapy improved outcomes throughout the entire follow-up period.
Conclusions:
- The proposed covariate-adjusted RMTL approach is interpretable and practical for evaluating treatment effects in observational competing risk data.
- This method enhances the analysis of cancer patient data, providing clearer insights into treatment efficacy over time.
Related Concept Videos
Comparing the Survival Analysis of Two or More Groups
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
The Mantel-Cox Log-Rank Test
Assumptions of Survival Analysis
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Odds Ratio

